Effectiveness and Safety of Herbal Medicine for Atopic Dermatitis: An Overview of Systematic Reviews
Autor: | Jaesuk Lee, Minjung Park, Nam-Kwen Kim, Suran Kim, Boram Lee, Chan-Young Kwon |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
MEDLINE Review Article Placebo law.invention Other systems of medicine 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life law Internal medicine medicine 030212 general & internal medicine SCORAD medicine.diagnostic_test business.industry Atopic dermatitis medicine.disease Systematic review Complementary and alternative medicine Itching medicine.symptom business RZ201-999 |
Zdroj: | Evidence-based Complementary and Alternative Medicine : eCAM Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020) |
ISSN: | 1741-4288 1741-427X |
DOI: | 10.1155/2020/4140692 |
Popis: | Objectives. Herbal medicine (HM) is attracting attention for treating atopic dermatitis (AD). This overview was conducted to summarize and critically evaluate the current systematic reviews (SRs) on HM for the treatment of AD. Methods. Through comprehensive searches, all relevant SRs on HM for AD published until May 2020 were included. The quality of included SRs was assessed using the AMSTAR-2 tool. Moreover, original randomized controlled trials (RCTs) included in the SRs were resynthesized to investigate the efficacy and safety of oral HM for AD. The quality of evidence for the main findings was evaluated using the GRADE approach. Results. Nine SRs were included in this overview. HM showed significantly better efficacy in terms of total effective rate (TER), itching and sleep symptom scores, quality of life, and the dose of topical treatment used compared with placebo. HM as a monotherapy and/or an adjunctive therapy to conventional medication (CM) showed significantly better results on the efficacy, symptom relief, and some laboratory parameters related to the inflammatory response. The methodological quality was generally low. When 58 original RCTs were reanalyzed, HM showed significantly lower SCORing Atopic Dermatitis (SCORAD) score and higher TER than the placebo or CM. In terms of the safety profile, HM was not significantly different from the placebo and was better than CM. The quality of evidence ranged from “moderate” to “very low.” Conclusion. The results suggested that HM as a monotherapy or an adjunctive therapy is promising for the treatment of AD. However, due to low methodological quality and low quality of evidence, further rigorous, well-designed, high-quality SRs, and RCTs are needed to make clinical recommendations on HM use. |
Databáze: | OpenAIRE |
Externí odkaz: |